Original Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Hepatol. Mar 27, 2013; 5(3): 97-103
Published online Mar 27, 2013. doi: 10.4254/wjh.v5.i3.97
Figure 1
Figure 1 Agrose gel electrophoresis of digested low molecular polypeptide-7 amplicons. Purified genomic DNA from each patient was subjected to polymerase chain reaction amplification using specific primers bracketing the low molecular polypeptide-7 gene followed by BsmI digestion and the products were resolved on 2% agarose gel. Lanes 2, 3 and 6 represent heterozygous C/A; Lanes 1 and 5 show C/C genotype; Lane 4 shows A/A genotype; M indicated molecular weight marker.
Figure 2
Figure 2 Frequencies of low molecular polypeptide-7 genotypes in control Egyptian subjects compared with chronic hepatitis C virus patients. Typing of low molecular polypeptide-7 (LMP-7) single nucleotide polymorphism was determined in 33 control subjects and 104 chronic hepatitis C virus patients. The frequency of each LMP-7 genotype in both patient groups was presented as columns.
Figure 3
Figure 3 Rates of sustained virological response and non-response among the three genotypes of low molecular polypeptide-7 gene. Genotyping of low molecular polypeptide-7 (LMP-7) was determined in 56 sustained virological response (SVR) patients and in 48 non-response (NR) patients. Rates of SVR (black column) and NR (white column) were independently plotted as a function of each LMP-7 genotype, i.e., CC, CA and AA.
Figure 4
Figure 4 The fibrosis stages among low molecular polypeptide-7 genotypes polymorphism in patient groups (sustained virological response and non-response) after treatment. Frequencies of low molecular polypeptide-7 genotypes were determined in chronic hepatitis C virus patients after treatment with different fibrosis scores (F0-F4).
Figure 5
Figure 5 Distribution of low molecular polypeptide-7 genotypes in chronic hepatitis C virus patients after treatment with various hepatic activities (A0-A3). Frequencies of low molecular polypeptide-7 genotypes in chronic hepatitis C virus patients after treatment with various hepatic activities (A0-A3).